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                                                             Abstract 
Opioid abuse and overdose are associated with substantial morbidity and mortality rates, 
as well as social and economic costs. The purpose of this study was to evaluate the 
independent and interactive effects of state-sponsored prescription drug monitoring 
program (PDMP) trained healthcare providers and community-based naloxone 
distribution program related factors in the states of Florida and Georgia for the prevention 
and reduction of prescription opioid use disorder, overdose, and deaths. The research 
theory adopted was the socio-ecological model with an emphasis on risk factors such as 
age. The study used secondary data from 2014 to 2018 from the Florida and Georgia 
Departments of Health. The statistical analysis results from one-way ANOVA and 
multiple linear regression revealed that there is a direct association between the number 
of state-sponsored PDMPs trained healthcare providers per year and the number of 
reported opioid overdoses, the number of opioid addiction treatment admissions, and the 
number of deaths attributed to opioid overdose-related deaths per year among adults 25 to 
64 years. The results also showed that there is an association between community-based 
naloxone distribution, the number of reported opioid overdoses, the number of opioid 
addiction treatment admissions, and the number of deaths attributed to opioid 
misuse/overdose per year among adults 25 to 64 years. The positive social impact of the 
study is that PDMPs, the education of healthcare providers, community use of naloxone, 
and practice guidelines will reduce misuse, abuse, addiction, diversion, and false 
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Section 1: Foundation of the Study and Literature Review  
Introduction 
The purpose of this study was to assess how various state-sponsored prescription 
drugs monitoring programs (PDMPs) training of healthcare providers on prescribing and 
dispensing of opioid drugs and community-based naloxone distribution program 
(CBNDP) events have contributed to the reduction of prescription drug use disorder and 
overdose. Opiate overdose persists as a significant public health problem, contributing to 
substantial morbidity and mortality among opiate users. In 2016, about 2 million 
Americans aged 12 and older admitted having an opioid use disorder (Rando et al., 2015; 
Reinhart et al., 2018). Drug overdose is currently one of the leading causes of preventable 
mortality in the United States (Rando et al., 2015). Opioids are the most common 
substances found in the single or poly cause of death (Rando et al., 2015). 
 Opioid overdose is one of the leading causes of injury-related death among 
Americans (age 25 to 64 years). From 1999 to 2018, there were more than 450,000 opioid 
overdose deaths. In 2018 alone, there were 47,000 opioid-related deaths in the US 
(Wilson et al. 2020). Approximately 45 deaths per day in the United States have been 
attributed to prescription opioids (Rando et al., 2015). Most of the overdose deaths are 
due to prescription opioid analgesics such as oxycodone, methadone, and hydrocodone 
(Li et al., 2014).  
Opioid overdose is a significant public health concern that affects a diverse group 
of individuals across all categories of race, class, and geography. Opioid-related 
overdoses are spreading demographically and geographically such as from urban areas to 




among non-Hispanic Whites, women, adolescents, young adults, and those with a history 
of chronic pain and depression (Colucci et al., 2014). Moreover, misuse and abuse of 
opioid analgesics have adverse health implications, including psychiatric illness (Colucci 
et al., 2014).  
According to Patrick et al. (2016), over 47,000 people died in the United States 
from drug abuse in 2014 alone, and 61% of those deaths were prescription opioid related. 
It is estimated that prescription overdose fatalities represent 63% of all overdose 
mortalities (Rudd, 2016). Naloxone has been frequently used to pharmacologically 
reverse overdoses by emergency service workers as well as peers or family members of 
overdose victims (Abraham et al., 2017). It is best to intervene within an hour of the 
onset of overdose symptoms (Abraham et al., 2017). 
The introduction of different state PDMPs with federal government funding 
assistance established statewide electronic databases of dispensed controlled substances 
(Li et al., 2014). Most states currently have (a) PDMPs, (b) prescription drug take-back 
days, (c) safe opioid prescribing guidelines, (d) education programs that seek to reduce 
opioid misuse and monitor and limit physicians and other healthcare providers on the 
number of opioids that can be prescribed or dispensed by using checks such as drug 
utilization review and prior authorization in insurance reimbursements, (e) mandatory use 
of state recommended guidelines and PDMPs, and (f) the distribution and administration 
of naloxone to at-risk patients (Faul et al., 2017). In this study, I sought to bring a 
positive change or social impact by seeking to inform and educate lawmakers, local 
authorities, and community leaders on the need to reduce and prevent prescription opioid 




statement, research questions, purpose of the study, literature review, definitions, 
assumptions, and delimitations. 
Problem Statement 
In recent years there has been an increase in the use of prescription opioids in the 
treatment of chronic non-cancer pain such as back pain and osteoarthritis despite the lack 
of long-term effectiveness and the risk of abuse (Centers for Disease Control and 
Prevention [CDC], 2019). According to the CDC (2019), opioid prescription overdose 
causes more than 34,000 deaths and 1.2 million emergency department visits annually. 
Most of the overdose deaths are due to prescription opioid analgesics such as oxycodone, 
methadone, and hydrocodone (Li et al., 2014). 
In 2015, more than 12 million Americans reported misusing opioid pain relievers 
(Abraham et al., 2017). According to the CDC (2018), between 1999 and 2016, there 
were more than 630,000 deaths due to drug overdose. In 2016, about 42,000 drug 
overdose deaths involved an opioid (CDC, 2018). Additionally, it is estimated that about 
115 Americans die daily from an opiate overdose (CDC, 2019). 
More than three out of five drug overdose deaths involve an opioid (CDC, 2019). 
Overdose deaths from opioids, including prescription opioids and heroin, have increased 
by five times since 1999 (CDC, 2019). Over 50% of those deaths were from prescription 
opioids (CDC, 2019). It is also alarming to know that the annual number of prescriptions 
for opioid analgesics has increased from approximately 75 million to almost 210 million 
in the past 20 years (CDC, 2019). 
The per capita consumption of prescription opioids has increased from 74 




(Li et al., 2014). Furthermore, research shows that about 25 million people are involved 
in the non-medical use of pain relievers in the past decade (Rutkow et al., 2015). 
Overdose related deaths are concentrated among the poor, racial and ethnic minorities, 
and individuals cycling in and out of the criminal justice system (Rutkow et al., 2015). 
Gap in Research 
Research on naloxone distribution and prescription overdose is limited. Some 
policymakers have argued that providing naloxone to opiate abusers may increase opioid 
use and delay admission to treatment centers (see Doe-Smith, 2014; Rowe et al., 2015). 
PDMPs are created to monitor controlled prescription usage and consequently reduce 
opioid abuse (Rutkow et al., 2015). There are currently limited studies that demonstrate a 
statistically significant association between the two variables (Rutkow et al., 2015). 
More so, studies evaluating the effectiveness of PDMPs in reducing opioid-
related mortality are limited. Research evaluating the effectiveness of specific 
characteristics of PDMPs is also limited. This could be due to their variability from state 
to state. For instance, some states have more controlled substance schedules than the five 
schedules from the Drug Enforcement Agency (Faul et al., 2017). Other states do not 
classify codeine cough syrups as controlled substances (Patrick et al., 2016). 
State policies could also contribute to the lack of research on the effectiveness of 
PDMPs. Some states mandate the registration and use of the PDMPs, while others only 
require periodic queries and specific algorithms to trigger a comprehensive investigation. 
The CDC guidelines on opioid prescribing, however, recommend the regular use of 




The opioid epidemic is driven by overprescribing (Faul et al., 2017). Efforts to 
prevent prescription opioid overdose include the legislation of different state laws that 
limit physicians and other healthcare providers on the number of opioids that can be 
prescribed or dispensed, the use of checks such as drug utilization review, and prior 
authorization in insurance reimbursements (Faul et al., 2017). The use of state prescribing 
guidelines and PDMPs is however mandatory (Faul et al., 2017). Finally, the distribution 
and administration of naloxone to at-risk patients is also highly recommended (Faul et al., 
2017). 
Purpose of the Study 
The purpose of this study was to evaluate and analyze how the number of state-
sponsored PDMPs trained healthcare providers and CBNDP could affect the misuse, 
abuse, addiction, diversion and falsely acquiring of prescription opioids. This quantitative 
study emphasized objective measurements, the statistical, mathematical, or numerical 
analysis of data collected through manipulating pre-existing statistical data using 
computational techniques (see Frost, 2019).  Healthcare provider education can reduce 
opioid prescribing by at least 40%, and result in fewer ER visits, leading to further 
reduction in opioid misuse, abuse, and addiction (Osborn et al., 2017) 
The independent variables include: (a) the number of state-sponsored PDMP 
trained healthcare providers, (b) the number of naloxone community-based distribution 
center opioid prescriptions written per year, (c) the number of naloxone community-
based distribution center prescriptions dispensed per year, (d) the number of naloxone 




dispensed per year, and (e) naloxone community-based distribution center opioid naïve 
patients per year.  
The dependent variables include: (a) the number of reported opioid overdoses per 
year among adults 25 to 64 years, (b) the number of opioid addiction treatment 
admissions per year, and (c) the number of opioid-related deaths per year among adults 
25 to 64 years. Controlling variables include the age group of patients and the gender of 
the patients.  
Research Questions and Hypotheses  
RQ1: Is there an association between the number of state-sponsored PDMPs 
trained healthcare providers and the number of reported opioid overdoses per year among 
adults 25 to 64 years? 
H01: There is no association between the number of state-sponsored PDMPs 
trained healthcare providers per year and the number of reported opioid overdoses 
per year among adults 25 to 64 years.  
H11: There is an association between the number of state-sponsored PDMPs 
trained healthcare providers per year and the number of reported opioid overdoses 
per year among adults 25 to 64 years. 
RQ2: Is there an association between the number of state-sponsored PDMPs 
trained healthcare providers and the number of opioid addiction treatment admissions per 
year among adults 25 to 64 years? 
H02: There is no association between the number of state-sponsored PDMPs and 





H12: There is an association between the number of state-sponsored PDMPs 
trained physicians and the number of opioid addiction treatment admissions per 
year among adults 25 to 64 years. 
RQ3: Is there an association between the number of state-sponsored PDMPs 
trained healthcare providers and the number of deaths attributed to opioid overdose-
related deaths per year among adults 25 to 64 years? 
H03: There is no association between the number of state-sponsored PDMPs 
trained healthcare providers per year and the number of opioid overdose-related 
deaths per year among adults 25 to 64 years. 
H13: There is an association between the number of state-sponsored PDMPs 
trained healthcare providers and the number of deaths attributed to opioid 
overdose-related deaths per year among adults 25 to 64 years. 
RQ4: Is there an association between community-based naloxone distribution and 
the number of reported opioid overdoses per year among adults 25 to 64 years? 
H04: There no association between community-based naloxone distribution and 
the number of reported opioid overdoses per year among adults 25 to 64 years. 
H14: There is an association between community-based naloxone distribution and 
the number of reported opioid overdose per year among adults 25 to 64 years. 
RQ 5: Is there an association between community-based naloxone distribution and 





H05: There is no association between community-based naloxone distribution and 
the number of opioid addiction treatment admissions per year among adults 25 to 
64 years. 
H15: There is an association between community-based naloxone distribution and 
the number of opioid addiction treatment admissions per year among adults 25 to 
64 years. 
 RQ6: Is there an association between community-based naloxone distribution and 
the number of deaths attributed to opioid misuse/overdose per year among adults 25 to 64 
years?  
H06: There is no association between community-based naloxone distribution and 
the number of deaths attributed to opioid misuse/overdose per year among adults 
25 to 64 years. 
H16: There is an association between community-based distribution and the 
number of deaths attributed to opioid misuse/overdose per year among adults 25 
to 64 years. 
Theoretical Foundation for the Study 
 The theoretical base for this study focuses on the social ecological model (SEM), 
initially developed by Bronfenbrenner (1992). The theory stipulates that children’s 
development is not only affected by their genetic or biological and psychological 
makeup, but also by their immediate physical and social environment, as well as the 
political and economic conditions in which they live in (Bukatko & Daehler, 2012). SEM 
is a multilevel framework which considers the different context and settings with which 




relationships with others, the institutions, and the communities in which they belong 
(CAPT-SAMHSA, 2016). 
 The SEM theory has been used as a health promotion tool in many public health 
interventions, such as obesity, smoke cessation, and diabetes management (CDC, 2019). 
SEM theorists emphasized the interactions between the different levels of factors which 
are interdependence and how that affects the individual’s health behavior. There are four 
levels to the SEM:  
• Individual level: Includes factors specific to the individual, such as age, 
education, income, and psychosocial problems. The individuals would be 
educated by their healthcare providers when an opioid prescription is written 
or dispensed to their peculiar individual characteristics. They would also be 
educated on the need to keep a naloxone spray when opioids are prescribed 
since a few doses of opioid prescriptions could cause addiction or overdose. 
• Relationship level: Includes an individual’s closest circle (e.g. family 
members, peers, and teachers) who contribute to their range of experiences 
that may influence behavior. Young people’s behavior is affected by the 
strong bond with their parents. This is because parents instill a sense of 
purpose in their children. These include the quest to aim high in life, finish 
school, get a degree, conform to school regulations, and be law-abiding 
citizens, among other values. 
• Community level: Includes the settings in which social relationships occur, 
such as schools, workplaces, neighborhoods, and community norms. Other 




environment, and lack of social support or access to resources in dealing with 
prescription drug abuse/overdose.  
• Societal level: Includes broader societal factors, such as social, religious, and 
cultural norms. Other social factors include health, economic, educational, 
social policies, law enforcement, public health education on drug abuse, 
availability of addiction treatment centers, state prescription opioid guidelines, 
prescription drug take-backs, state-sponsored PDMPs, CBNDPs, and health 
providers’ continued education of effective pain management and drug abuse 




SEM Model. Adapted from Centers for Disease Control and Prevention; Division of 







 (Available at https://www.cdc.gov/nccdphp/dnpao/state-local-programs/health-
equity/framing-the-issue.html) 
This study on state-sponsored PDMPs and CBNDPs considered all the socio-
ecological factors that influence the individual’s health behavior at all levels of the SEM 
to reduce the rate of prescription opioid overdose, decrease admissions to addiction 
treatment centers, and reduce overall overdose-related fatalities. 
Nature of the Study 
Study designs are essential for the quality, execution, and interpretation of public 
health research. The choice of study design however depends on funding, time 




or correlation study design to be the appropriate observational study for this research. An 
ecological study design compares clusters of people based on their geographical location. 
Since this study purposed to use secondary data from the state-sponsored PDMPs’s 
database, the ecological or correlation design was adopted. Ecological or correlation 
studies are also quick and inexpensive. Additionally, its analysis and presentation are 
simple and easy to understand. They are also noted to achieve a broader range of 
exposure levels than individual-level studies (Omair, 2015; Thiese, 2014). 
This study’s limitations include ecological fallacy or bias, that is, the lack of 
individual-level information and the inability to control confounders and possible 
inaccuracy of the data used. The unit of analysis is the population, not the individuals. 
This means any associations observed between the variables at the population level do 
not necessarily translate to the individual level (Aschengrau & Seage, 2014; Omair, 2015; 
Thiese, 2014). 
The independent variables include the number of state-sponsored PDMPs trained 
healthcare providers, opioid prescriptions written and dispensed, the number of opioid 
prescriptions with morphine milligram equivalence (MME) above 90 milligrams, and the 
number of opioid naïve patients (patients who have never used prescription opioids or 
have not used prescription opioids in 6 months or more.) 
The dependent variables include the number of reported opioid overdoses per 
year, the number of opioid addiction treatment admissions per year, and the number of 
opioid-related deaths per year among adults 25 to 64 years. The controlling variables 













RQ 1: Is there an association between 
the number of state-sponsored PDMPs 
trained healthcare providers per year 
and the number of reported opioid 
overdoses per year among adults 25 to 
64 years? 
The number of PDMP 
trained healthcare providers 
per year 





RQ 2: Is there an association between 
the number of state-sponsored PDMPs 
trained healthcare providers and the 
number of opioid addiction treatment 
admissions per year among adults 25 to 
64 years? 
The number of PDMP 
trained healthcare providers 
per year 






RQ 3: Is there an association between 
the number of state-sponsored PDMPs 
trained healthcare providers and the 
number of deaths attributed to opioid 
overdose-related deaths per year 
among adults 25 to 64 years? 
The number of state-
sponsored PDMPs trained 
healthcare providers per 
year 





RQ 4: Is there an association between 
community-based naloxone 
distribution and the number of reported 
opioid overdoses per year among adults 
25 to 64 years? 
Community-based naloxone 
distribution (the number of 
opioid prescriptions written 
and dispensed) per year 





RQ5: Is there an association between 
community-based naloxone 
distribution and the number of opioid 
addiction treatment admissions per 
year among adults 25 to 64 years? 
Community-based naloxone 
distribution (the number of 
opioid prescriptions with 
MME higher than 90mg) 






RQ 6: Is there an association between 
community-based naloxone 
distribution and the number of deaths 
attributed to opioid misuse/overdose 
per year among adults 25 to 64 years? 
Community-based naloxone 
distribution (the number of 
opioid naïve patients) 








Literature Search Strategy 
I used a literature search strategy to identify search engines and databases related 
to the research problem. The general search produced existing peer-reviewed papers as 
well as government reports on the opioid epidemic. I further searched the SAMSHA and 
CDC websites for data and information related to the research problem. The literature 
review was also done using peer-reviewed published articles found PubMed, Library of 
Congress, ECHBOST, and Medline with full-text abstracts, Cochran Library, Google 
Scholar, Pro-Quest Nursing and Allied Health Services, and CINAHL. The search terms 
included prescription opioids, abuse, misuse of opioid therapy, drugs, narcotics, 
substance abuse, pain management, controlled substances monitoring and diversion, 
healthcare, emergency departments, naloxone distribution, prescription drug monitoring 
programs, overdose, and drug fatalities.  
The scope of the literature search included only peer-reviewed literature published 
within the last 5 years. Literature including primary research articles, literature review 
articles, secondary research articles with contents relating to either the clinical or 
economic effects of prescription opioid abuse, treatment, and overdose, and standing 
orders for naloxone distribution in various states and communities, as well as opioid 
overdose fatalities were selected and reviewed. The search however excluded non-
English articles, newspaper articles, and non-peer-reviewed journals. 
Literature Review Related to Key Variables and/or Concepts 
This study sought to evaluate and analyze how various state-sponsored PDMP’s 
and community-based naloxone distribution programs have contributed to the prevention 




variables such as age, gender, neighborhoods, and geographical location. The dependent 
variables considered included the volume of opioid prescriptions prescribed and 
dispensed, the number of healthcare providers trained to use PDMPs and counsel patients 
on naloxone use. More so, the number of opioid naïve patients, the number of days for 
the supply of prescription opioids, the morphine milligram equivalence of the opioids 
prescribed as well as the opioid overdose mortalities were all considered. 
Prescription opioid abuse is a growing public health threat especially to the United 
States of America (USA). Millions of Americans are struggling with prescription opioid 
abuse, with thousands losing their lives due to its overdose. Medical professionals directly 
or indirectly influence the prescription opioid abuse epidemic through their prescribing 
habits (SAMSHA, 2018). Opioid abuse is also associated with downstream cases of 
infections related to intravenous injections such as HIV/AIDS, Hepatitis B, and C 
endocarditis, pyogenic spinal infections, osteomyelitis, septic arthritis, and epidural 
abscess (Ronan & Herzig, 2016). Hospital admissions concerning prescription opioid 
misuse and dependence have nearly doubled between 2000 and 2012. The rate of opioid-
related inpatient stay has increased from 136.8 per 100,000 population in 2005 to 224.6 per 
100,000 population in 2014. During this same period, the rate of opioid-related emergency 
department visits increased by 99.4 percent, from 89.1 per 100,000 population in 2005 to 
177.7 per 100,000 population in 2014 (Weiss et al., 2017). 
According to the CDC, the number of opioid prescriptions has more than 
quadrupled since the nineties. Research shows that at least one in every four patients given 




of opioid use disorder, risky behaviors, compulsive use, and physiological dependence 
(CDC, 2019; SAMSHA, 2019). 
The National Institute on Drug Abuse (NIDA), in partnership with the Appalachian 
Regional Commission (ARC), are working together to address the dramatic increase in 
prescription opioid drug use in Appalachia. Research has shown that rural communities 
along the Appalachian are more likely to have a high incidence of opioid abuse, misuse, 
and overdose (Singhal et al., 2016). 
Individuals who misuse and abuse opioids tend to live in rural areas and are 
generally older than heroin users who tend to live in urban areas. Unintentional opioid 
overdose deaths are more common among adults between the ages of 45 to 64 and are even 
higher among adults between the ages of 25 and 34 (Pualozzi, 2014). Increases in opioid 
overdose fatalities among older individuals are a significant factor in the increases in opioid 
prescribing rates. Research shows that people over the age of 65 are prescribed an average 
of two opioids per prescription when visiting their doctors (Pualozzi, 2014).  
Prevention Interventions 
Effective opioid abuse interventions must be directed towards the highest risk 
groups. Any form of intervention should involve the individual, family, friends, healthcare 
providers, community leaders, and law enforcement agencies (Paulozzi, 2014). Easy access 
to state-sponsored Prescription Drug Monitoring Programs (PDMPs) and availability of 
naloxone are also key factors to consider. Training of healthcare providers to identify at-
risk patients and preventing opioid prescription misuse and abuse is a key strategy to be 




  According to the CDC (2019), people who are more likely to abuse prescription 
opioids exhibit certain physical and psychological behaviors, such as irritability, urgency, 
or anxiety. They frequently attempt to obtain prescription opioids from multiple providers 
and pharmacies, try to fill opioid prescriptions earlier than time, and continuously change 
healthcare providers.  
Abuse-deterrent formulations use opioid antagonist agents and chemicals that 
induce unpleasant symptoms when taken excessively. Manufacturers also incorporate 
physicochemical properties into the drug, making it difficult to extract the active 
ingredients from the tablet or capsule (Coplan et al., 2016). 
 In 2010, the manufacturer of Oxycontin (oxycodone extended release) 
reformulated the drug with a polyethylene oxide matrix. This matrix hardens the tablets 
which creates physicochemical barriers to deter breaking, crushing, and dissolving, making 
it harder to extract oxycodone and decrease the rate of abuse (Coplan et al., 2016). 
Kentucky’s rate of OxyContin abuse has reduced from 85% to 30% after the introduction 
of the reformulated drug. Data from the National Survey of Drug Use and Health (NSDUH) 
published by SAMSHA shows that past year initiation of non-medical use of OxyContin 
decreased by 18%, 37%, 26%, and 49% over the years from 2011 to 2014 respectively, 
relative to the 695,000 users in 2009 (Coplan et al., 2016). Patients with prescription 
opioids with a morphine milligram equivalence (MME) of 100mg/day or more are nine 







Socio-Economical and Behavioral Impact 
According to the National Epidemiologic Survey on Alcohol and Related 
Conditions (NESARC), a survey from 2014 to 2015 shows that young adults aged 18 to 24 
are more likely to misuse or abuse opioid prescription and alcohol than adults aged 25 to 
64 years (Coplan et al., 2016; Rudd et al., 2016). Research shows that opioid abuse and 
overdose are associated with mental health disorders. People with mental health and 
behavioral issues such as mood disorders, major depression, dysthymia, mania, and 
hypomania, anxiety disorders (e.g. panic disorders with and without agoraphobia), social 
phobia, and generalized anxiety disorder are more vulnerable to opioid misuse and abuse.  
            Patients with a past medical history of substance abuse or prescription opioid use, 
mental health issues (e.g., PTSD, depression, anxiety) mentally demanding occupations, 
older adults, dysfunctional social environment, and lower self-efficacy are highly 
vulnerable to prescription opioid abuse (Chou et al., 2016; Currow et al., 2016; Denenberg 
& Curtis, 2016). 
The complexity of prescription opioid misuse and abuse is further confounded by 
an individual’s demographics such as age, sex, race/ethnicity, educational background, 
marital status, and household income (Denenberg & Curtis, 2016). The rise in prescription 
opioid misuse and abuse is mostly due to increasing therapeutic use, and newer varying 
prescribing guidelines in different states (Brady et al., 2017). According to the Treatment 
Episode Data Set, the treatment admission rate for individuals abusing prescription opioids 
has increased from 7 to 36 per 100,000 population between 1997 and 2007. Opioid-related 




      Research shows that opioid misusers or abusers between the ages of 25 and 64 years 
are more likely to utilize medical services, such as the emergency department, mental 
health outpatient clinics, and inpatient hospitals (Meyer et al., 2014). According to the Drug 
Abuse Warning Network (DAWN), emergency department visits involving prescription 
opioid abusers increased by more than 100% from 2004 to 2008. According to the White 
House Budget Office, it is estimated that prescription drug abuse, days of work loss, 
healthcare providers visits/services, and criminal justice cost the government nearly 300 
billion dollars annually (Meyer et al., 2014). 
A recent meta-analysis by Brady et al. (2017), indicated that a higher proportion of 
males suffer from prescription opioid misuse, abuse, and overdose. Also, individuals of 
either gender, aged 25 to 54 are at the highest risk of abuse prescription opioids. Individuals 
afflicted with psychotic disorders or had widespread substance abuse issues were more 
likely to abuse prescription opioids (Brady et al., 2017). 
All patients, including opioid-naïve patients, should be screened for potential risk 
of abuse before starting opioid therapy. Patients on opioid therapy should receive education 
regarding the safe use, storage, and disposal of prescription opioids. Also, taking the 
medications as directed, acquiring them from only one provider, not sharing drugs with 
friends and family, and not taking medications with alcohol are important precautions to 
be adhered to (Brady et al., 2016). 
Long-term use of prescription opioids could precipitate the risk of tolerance, 
physical dependence, and withdrawal symptoms when stopped abruptly. Tolerance effects 
of medications cause the need to increase the currently prescribed dosages to be effective. 




blood pressure, pupillary dilation, goosebumps, anxiety, jittery behavior, nausea, diarrhea, 
runny nose, yawning, myalgia, and insomnia. These withdrawal symptoms could 
sometimes be treated with alpha-blocking agents like clonidine or tapering of opioid 
prescriptions (Chou et al., 2016; Currow et al., 2016; Denenberg & Curtis, 2016). 
 Concurrent use of opioids with neuron-depressants or sedation medications 
increases the risk of sedation, hypoventilation, falls, accidents, and sudden unintentional 
death. Long-term opioid therapy also increases the risk of cardio-respiratory events or 
myocardial infarction in patients with sleep apnea and end-stage respiratory disease (Chou 
et al., 2016; Currow et al., 2016; Denenberg & Curtis, 2016). 
Research shows that as the dose of the prescription opioid increases, so does the 
risk of abuse or dependence. Higher doses are also associated with increased cases of 
worker's disability compensation. Prescribing doses less than 120 MME/daily reduces the 
rate of mortality due to overdose. Ideally, the appropriate dosing of prescription opioids is 
between 40 and 90 MME per day (Manchikanti et al., 2012). 
Prescribing opioids to the elderly must be done with caution doses equal to or 
higher than 50 MME daily doubles their risk of falls and fractures. Furthermore, 
prescribing opioids to pregnant women increases the risk of congenital disabilities, neural 
tube defects, congenital heart defects, gastroschisis, poor fetal growth, neonatal opioid 
withdrawal syndrome, and stillbirths (Chou et al., 2016; Yazdy et al., 2013). 
However, non-pharmacological interventions include relaxation, guided imagery, 
acupuncture, massage, acupressure, aromatherapy, reflexology, yoga therapy, music 




therapy, exercise, physical therapy, and epidural and steroid injections (Denenberg & 
Curtis, 2016; Gregory, 2014; Hooten et al., 2013; Rosenberg, 2013). 
Naloxone use 
Naloxone is an opioid receptor antagonist with no potential for abuse, which 
reverses the effects of opioids in cases of respiratory depression and decreased 
consciousness during an overdose. Naloxone produces little detectable pharmacological 
action without the presence of an opioid agonist (Coe & Walsh, 2016; Doe-Simkins et al., 
2014). Access to and the use of naloxone is an essential tool in prescription opioid overdose 
prevention. Distribution of naloxone is a safe, feasible, and effective intervention in 
community settings. Also, laypersons can safely administer intranasal naloxone after brief 
training (Drainoni et al., 2016). Distribution of naloxone to individuals who may witness 
an overdose through community-based naloxone and overdose education programs have 
shown a reduction in overdose deaths in these communities (Jones et al., 2016). 
Recent legislative changes in several states have however allowed naloxone to be 
administered by first responders, law enforcement officers, healthcare providers, family 
members, and friends, as well as bystanders to an opioid, overdosed individual (Abuse, 
2018; Coe & Walsh, 2016). Naloxone could also be dispensed to patients with a history of 
overdose, substance abuse disorder, or those prescribed opioid medications (Abuse, 2016; 
Currow et al., 2016). 
Community-based distribution of naloxone in combination with proper prescription 
opioid therapy decreases prescription overdose risk and mortality (Walley et al., 2013). 
Many states now have "Standing Orders" (agreements with pharmacies and hospitals to 




Project Lazarus, a community-based overdose prevention program in Wilkes 
County North Carolina, has recorded a 50% reduction in opioid-related deaths since its 
inception. The program engages local prescribers, pain patients, and various non-medical 
prescription opioid users to reduce opioid abuse and overdose. The program advocates and 
offers naloxone as part of routine medical care to suspected prescription opioid abusers and 
pain patients who are at high risk for overdose (Coe & Walsh, 2016; Doe-Simkins et al., 
2014). 
Naloxone dispensing is recommended for individuals such as patients who have 
been recently prescribed or treated with prescription opioids, suspected or confirmed 
history of non-medical opioid use, or patients with a high dose of opioid prescription (doses 
=100 MME) (Coe & Walsh., 2016). It is also recommended for opioid naïve patients who 
have prescribed methadone, patients just recently released from prison, or mandatory 
abstinence drug detox/program. Also, patients who have respiratory issues or disease (e.g. 
asthma, COPD, emphysema, sleep apnea, smoker) are prescribed opioids (Coe & Walsh, 
2016; Doe-Simkins et al., 2014). Naloxone could also be dispensed to patients with a 
history of alcohol or harmful substance abuse, abuse of benzodiazepines, psychiatric 
disorders, or cognitive impairments who are prescribed opioids (Coe & Walsh, 2016). 
From 2013 to 2015, naloxone prescriptions dispensed in the United States has 
increased more than ten (10) times. The same period notes a 187% increase in naloxone kit 
distributed by community-based organizations, which have resulted in a 160% increase in 
opioid overdose reversals (Jones et al., 2016). 
Meanwhile, the significant adverse effect of naloxone in opioid-dependent patients 




displacement of opioid agonists from the opioid receptors. However, naloxone has no 
abuse potential or psychoactive properties when used for long-term (Mueller et al., 2015). 
The potential issue of stigma and mistrust that may surround naloxone prescribing 
can be avoided by educating patients on the risk of respiratory depression from prescription 
opioid use. The notion that prescription opioid abusers see naloxone as a “safety net,” and 
hence increase opioid abuse, risky behaviors, and delay entry into addiction treatment is 
false and has no scientific evidence (Coe & Walsh, 2016; Doe-Simkins et al., 2014). 
Prescription Drug Monitoring Programs  
Prescription Drug Monitoring Programs (PDMPs) are intended to detect and reduce 
abuse, misuse, and diversion of controlled substances to reduce associated harm as well as 
provide necessary information to enable healthcare providers offer appropriate medical 
care (Paulozzi et al., 2012; Islam & McRae 2014). 
The PDMPs also collect information on the individual patient's such age, gender, 
payment method (e.g. insurance or cash), and the dispensing facility. They also give 
information on the rate of prescribing and dispensing by both prescribers and pharmacies, 
and on individuals receiving a combination of controlled substances such as opioids and 
benzodiazepines. Data from the PDMP can help identify patients at risk of addiction as 
well as those who might be diverting controlled substances. Such individuals tend to shop 
from multiple providers and obtain controlled substances from different pharmacies in a 
relatively short period. Research shows that effective PDMP increases clinicians’ 
confidence in opioid prescribing, help identify and reduce doctor shopping, and monitor 




The effectiveness of PDMP could be assessed by monitoring the system and its 
interoperability with other state programs such as addiction treatment centers (Coplan et 
al., 2016). In a survey conducted by Liebling et al. (2016), out of 200 participants, about 
42% of people who misuse or abuse prescription opioids are classified as self-treaters 
whose main objective is to relieve pain. The survey also found that 24% of the participants 
use prescription opioids for recreational purposes, whiles 34% are mixed users (self-
treaters and recreational users). Research shows that recreational and mixed users are more 
likely to be alcohol and illicit drug abusers (Coplan et al., 2016). Due to the interaction 
between opioids and certain psychiatric medications such as benzodiazepines, barbiturates, 
and other antidepressants, psychiatric patients are at increased risk of opioid overdose. 
PDMPs ensure the appropriate use of controlled substances and detect diversion of 
controlled substances. The information on demographic and geographical locations of 
potential abusers enables public health providers to effectively implement intervention 
programs (Brady et al., 2016). 
Studies show that Florida had more than 80% increases in prescription drug 
overdose deaths from 2003 to 2009 due to the abundance of pill mills. This was primarily 
caused by doctor offices, clinics, or pharmacies, which prescribe and dispense controlled 
medications to individuals with no legitimate medical purpose (Rutkow et al., 2015; 
Delcher et al., 2015). 
In Florida, the acquisition and distribution of opioid prescriptions, regarding MME 
dropped by approximately 36% during the same period. It is also reported that the rate of 
oxycodone diversion in Florida declined by 29% in the quarter after PDMP 








• It is a chronic disease of brain reward, motivation, and memory circuitry, which is 
characterized by a person’s inability to abstain consistently, impaired behavior 
control, craving, and a dysfunctional emotional response (Lin, 2013). 
Doctor shopper 
• This is when a patient seeks prescriptions from multiple providers without revealing 
to each prescriber that other sources are involved. Individuals visiting more than 
one provider and pharmacy for opioids during a specified period provide the basis 
for this characterization. For example, an individual who uses more than five 
prescribers for the same schedule of opioids in one calendar year is referred to as a 
doctor shopper (Wilsey et al., 2013). 
Drug misuse 
• This is the use of a drug for purposes for which it was not intended or using a drug 
in excessive quantities. It is the use of controlled drugs with higher doses, or for a 
more extended period than prescribed or the use of a prescription for a reason other 
than the condition for which they were prescribed (Wise & Koob, 2014). 
Opioid addiction  
• It is the powerful, compulsive urge to use opioid drugs even when they are no longer 





• This occurs when people consume opioids over a long period and develop physical 
and psychological withdrawal symptoms such as muscle cramping, diarrhoea, and 
anxiety (Wise & Koob, 2014).  
Opioid overdose 
• This happens when there are so many opioids or a combination of opioids and other 
drugs in the body that the victim is not responsive to stimulation, and breathing is 
inadequate (Harm Reduction Coalition, 2018). 
Unintentional poisoning 
• This involves the use of drugs or chemicals for recreational purposes in excessive 
amounts.  
Standing Order 
•  This is a written document formulated collectively by the professional members of 
a department or healthcare facility that could contain rules, policies, procedure, 
regulations, or prescription orders for patient care (Lin, 2013). 
Assumptions 
The study assumes that strict and accurate application of the state-sponsored PDMP 
regulations, as well as the availability of affordable and easily accessible naloxone by 
patients at risk or their relatives, would result in a decrease in prescription opioid abuse 
and overdose. This assumption is because the state reports on prescription opioid addiction 
treatment and admissions decreased with the implementation of state-sponsored PDMPs 




Scope and Delimitations 
Research shows that healthcare providers often lack the confidence to safely 
prescribe opioid prescriptions or the ability to detect potential prescription opioid misuse 
or abuse. They also lack the initiative or expertise to discuss the topic and consequences of 
prescription opioid misuse or abuse with patients. Even though healthcare providers 
acknowledge the use of prescription opioids to relieve moderate to severe pain, they have 
a more significant concern about opioid abuse or addiction (Hwang et al., 2015). 
Some prescribers are reluctant to prescribe controlled substances due to fear of the 
legal repercussions. This results in the prescribing of alternative medications with less 
effectiveness or more significant side effects. There is however a lack of uniformity and 
knowledge in the use of opioid prescribing guidelines, as well as risk assessment tools to 
prevent prescription opioid abuse. More so, the requirements to register and access the 
PDMP information appears cumbersome to some healthcare providers, and interpretation 
of the information hinders progress in their work (Ringwalt et al., 2014; Rosenberg, 2013; 
Islam & McRae, 2014). In general, healthcare providers also lack experience and exposure 
to opioid-related events and thus fear regulators and law enforcement breathing down their 
necks (Abuse, 2018). There is the need to update guidelines across the state regularly and 
nationwide, and to further compare guidelines across neighboring states for uniformity 
(Abuse, 2018). 
Patients fear the scrutiny from law enforcement if they use medications monitored 
by the PDMP. They might also worry about the additional cost of required monthly visits 
to the physician's office since such controlled drugs cannot be refilled without office visits. 




or privacy. The public also views PDMP as a law enforcement tool rather than assisting in 
safe therapy management. It therefore involves additional time and puts pressure on the 
prescribers (Islam & McRae, 2014). 
Research shows that young adults aged 18 to 25 use prescription opioids non-
medically and are unwilling to seek treatment due to lack of trust and stigmatization. 
Additionally, healthcare professionals who happen to use prescription opioids non-
medically refuse to seek treatment due to perceived discrimination and stigmatization. 
Other barriers include those inherent in the healthcare system such as treatment structure, 
waiting times, payment methods, and confidentiality (Liebling et al., 2016). 
Significance, Summary, and Conclusions 
Life expectancy in the U.S.A is affected by the high rates of mortality in people 
under 50 years of age who are dying due to unintentional drug overdose (Green et al., 
2015). PDMPs help healthcare providers to identify potential abusers, doctor shoppers in 
different states and help to educate people on the need to use opioid prescribing guidelines 
to reduce opioid misuse (Reisman et al., 2009; Li et al., 2014). Currently, there have been 
about 644 community-based naloxone distribution programs in the U.S.A, with an estimate 
of over 27,000 overdose reversals annually (Green et al., 2015).  
Research shows that emergency department visits involving misuse or abuse of 
prescription opioids have increased by 153% between 2004 and 2011 (Compton et al., 
2016). Community-based programs in States such as New Mexico, Massachusetts, and 
New York have implemented successful naloxone distribution and overdose prevention 




Research shows that community-based programs could result in about 74 % confirmed 
opioid overdose reversals (Rutkow et al., 2015). 
Furthermore, there are currently many legislative changes in different states to 
increase naloxone access to those at risk of opioid overdose. Many states have also passed 
laws and issued standing orders that allow prescribers and pharmacists to prescribe and 
dispense naloxone to people other than the person at risk of overdose such as friends and 





Section 2: Research Design and Data Collection 
Introduction 
Opioid drug misuse and dependence is a major social and public health problem 
in the United States that has reached epidemic levels in the past few decades (Rudd et al., 
2016). Indeed, about 2 million U.S. adults abused or were addicted to prescription 
opioids in 2014 (Hedden, 2015). Researchers have found that at least one in every four 
people who have received prescription opioids for pain not related to cancer become 
addicted at some point (Boscarino et al., 2015). Almost 50% of all deaths related to 
opioid misuse involve a prescription opioid (Kolodny et al., 2015).  
  It is clear that dependence on opioids inflicts enormous social and economic costs 
as a result of lost productivity, breakdown in relationships, healthcare costs, and expenses 
related to law enforcement. Prescription opioid misuse and dependence cost the U.S. 
economy a projected $78.5 billion (Florence et al., 2016).   
In this study, data from 2014 to 2018 in Florida and in Georgia were compared 
and analyzed separately to assess the effect of state-sponsored PDMPs as well as the 
impact of naloxone standing orders and the availability of naloxone to at-risk patients or 
their relatives without prescription.   
Research Design and Rationale 
The study relied on using secondary data to determine the association between the 
implementation of state-sponsored PDMPs and prescription opioid abuse/overdose as 
well as the effect of state-issued standing orders to make naloxone readily available to 




An observational study was however the appropriate study design for this study. 
Observational studies can be used to study the effects of a broader range of exposures and 
diseases in the population to draw inferences on the prevention, treatment, and possible 
causes of the disease. This type of study also helps to provide information to explain the 
causes of disease incidence and the determinants of disease progression to predict the 
future healthcare needs of the population and to control diseases by studying ways to 
prevent them as well as prolong the lives of those who have the disease. The two main 
subtypes of observational study are descriptive and analytic studies (Aschengrau & 
Seage, 2014; Omair, 2015; Thiese, 2014). 
The study also adopted the ecologic research design approach, which is an 
observational analytic study. In an ecological study, the unit of analysis is the group. The 
rate of exposure or exposed person and the rate of disease or the number of cases is 
known. However, the number of exposed cases is unknown. This study involves an 
assessment of the association between exposure rate (which is the availability of 
prescription opioids through written or dispensed prescriptions) and disease rate (which is 
the use/abuse and overdose) among different age groups and gender. This also includes 
finding out the incidence rates, prevalence rates, and mortality rates of the disease 
(Aschengrau & Seage, 2014; Omair, 2015; Thiese, 2014). 
Ecologic studies are quick, simple to conduct, and inexpensive. However, the 
level of exposure of each individual in the unit being studied is not known. Besides, the 





The use of a quasi-experimental design was inappropriate for this study since it 
only gives information on whether the implementation or introduction of a public health 
program or policy was successful or failed. It also involves the manipulation of the study 
factors but not the randomization of the study subjects. Thus, it only evaluates the extent 
to which a program meets their public health goals (Aschengrau & Seage, 2014; Omair, 
2015; Thiese, 2014). 
The establishment of PDMPs through various state legislations and the granting 
of standing orders to dispense naloxone to at-risk patients have tremendously affected the 
abuse/overdose of prescription opioids. PDMPs and naloxone distribution have 
contributed to the slow down or curtailing of the opioid epidemic in the U.S. Many states 
now have laws that require providers and pharmacists to record any controlled substance 
prescription written or dispense within 24 hours of issuance. This allows current data to 
be accessed in the shortest possible time to determine the current trend of prescription 
opioid abuse/overdose. The data would also include the number of trained personnel who 
may use the PDMP program, such as licensed prescribers (which include optometrists, 
physicians, nurse practitioners, physician assistants, dentists, pharmacists, and law 
enforcement officers). 
Methodology 
This study adopted a quantitative research approach where existing data from 
various state health departments were collated and analyzed. The data included the 
annual reports for the last 5 years from the states PDMPs and drug overdose mortalities. 
Emails were sent to the various state’s public health departments for quarterly and annual 




The Target Population 
 The population target is all patients in the states of Florida and Georgia who have 
prescribed opioid prescriptions in the past 5 years. The data includes personal data (i.e., 
age and gender) but not the patients’ names, addresses, or any identifiable data to link a 
person’s identity to this study. 
The Sample Frame 
The sample frame is all controlled substance prescriptions recorded in the states’ 
PDMP data between the years 2014 and 2018 in Florida and Georgia. The PDMP collates 
all the controlled substance prescription data from both healthcare providers and 
pharmacies. 
Sampling and Sampling Procedures 
The sampling process for this study was done by using convenient sampling. 
Convenience sampling is a non-probability sampling technique where subjects are 
selected because of their convenient accessibility and proximity to the researcher. Data 
was therefore obtained from the PDMP annual reports from the department of health 
websites for the states of Florida and Georgia because that was the most convenient 
source of the data needed. 
Data from the National Survey on Drug Use and Health (NSDUH) from the 
SAMSHA website with regard to Florida and Georgia were also collected. The NSDUH 
is a nationwide survey of civilian non-institutionalized population aged 12 years and 
older in the United States of America. The survey excludes individuals with no fixed 
household address, active-duty military personnel, and residents of institutional groups. 




individuals were asked their willingness to report honestly about sensitive topics such as 
illicit drug use behavior and mental health issues. Confidentiality was emphasized in all 
written and oral communications with each respondent and their identities were 
protected. This was also ensured in cases where private interviews were performed using 
computer-assisted interviewing methods where researchers read questions from a 
computer or laptop and entered the responses.  
Sample Size 
The number of people interviewed in Florida in 2013 was 3,600 and in Georgia 
was 900. The number of people interviewed between 2014 and 2018 was 3,300 in Florida 
and 1,500 in Georgia. The selected age groups were 18-25, 26-34, 35-49, 50-64, and 65 
or older, respectively. The sample was also made up of Hispanic, White, and Black 
respondents. The gender was male or female. Even though the NSDUH survey involved 
multiple questions on drug use and mental health, this study focused only on the opioid 
prescription data, which included hydrocodone, oxycodone, tramadol, codeine, morphine, 
fentanyl, hydromorphine, oxymorphine products, and methadone. 
Instrumentation and Operationalization 
Data from 2014 to 2018 provided by the PDMP program in Florida and Georgia 
were gathered. This was done by contacting the Electronic-Florida Online Reporting of 
Controlled Substance Evaluation (E-FORCSE) agency responsible for the state PDMP 
program in Florida and Georgia, the Epidemiology Section of the Department of Public 
Health accountable for the state PDMP program. The PDMPs collect prescription 




controlled substances. The classification is based on the medication’s potential for abuse, 
if it is accepted as a medical treatment, and the safety of its use, as follows: 
• Schedule 1 drugs have the highest potential for abuse, but currently have no 
medical use and no safety use. Examples include heroin and cocaine.  
• Schedule II drugs have a high potential for abuse and have current medical 
use but may lead to severe physical and psychological dependence. Examples 
include Oxycodone, Hydrocodone, and Ritalin. 
• Schedule III drugs have the potential for abuse; they have medical use but 
may lead to moderate physical and psychological dependence. Examples 
include steroids and some codeine products. 
• Schedule IV drugs have a low potential for abuse; they have medical use but 
may lead to limited physical and psychological dependence. Examples are 
Xanax, Ambien, and Tramadol. 
• Schedule V drugs have a low potential for abuse; they have medical use but 
may lead to limited physical and psychological dependence. Examples are 
Lyrica and Lomotil. 
In this study, I gathered data mainly on schedule II prescription opioids. The data 
contained the gender and age of the patients. However, all the personal identities of the 
patients were excluded. The age groups considered were adults 25 to 64 years. The data 
was coded and entered using the IBM SPSS version 25.0 (IBM, 2017). I conducted 
descriptive, inferential analysis of variance and multiple linear regressions of the 




Research Questions and Hypotheses  
RQ1: Is there an association between the number of state-sponsored PDMPs 
trained health care providers per year and the number of reported opioid overdoses per 
year among adults 25 to 64 years? 
H01: There is no association between the number of state-sponsored PDMPs 
trained healthcare providers per year and the number of reported opioid overdoses 
per year among adults 25 to 64 years. 
H11: There is an association between the number of state-sponsored PDMPs 
trained healthcare providers per year and the number of reported opioid overdoses 
per year among adults 25 to 64 years. 
RQ2: Is there an association between the number of state-sponsored PDMPs 
trained healthcare providers and the number of opioid addiction treatment admissions per 
year among adults 25 to 64 years? 
H02: There is no association between the number of state-sponsored PDMPs and 
the number of opioid addiction treatment admissions per year among adults 25 to 
64 years. 
H12: There is an association between the number of state-sponsored PDMPs 
trained physicians and the number of opioid addiction treatment admissions per 
year among adults 25 to 64 years. 
RQ3: Is there an association between the number of state-sponsored PDMPs 
trained healthcare providers and the number of deaths attributed to opioid overdose-




H03: There is no association between the number of state-sponsored PDMPs 
trained healthcare providers per year and the number of opioid over dose-related 
deaths per year among adults 25 to 64 years. 
H13: There is an association between the number of state-sponsored PDMPs 
trained healthcare providers and the number of deaths attributed to opioid 
overdose-related deaths per year among adults 25 to 64 years. 
RQ4: Is there an association between community-based naloxone distribution and 
the number of reported opioid overdoses per year among adults 25 to 64 years? 
H04: There no association between community-based naloxone distribution and 
the number of reported opioid overdoses per year among adults 25 to 64 years. 
H14: There is an association between community-based naloxone distribution and 
the number of reported opioid overdose per year among adults 25 to 64 years. 
RQ 5: Is there an association between community-based naloxone distribution and 
the number of opioid addiction treatment admissions per year among adults 25 to 64 
years? 
H05: There is no association between community-based naloxone distribution and 
the number of opioid addiction treatment admissions per year among adults 25 to 
64 years. 
H15: There is an association between community-based naloxone distribution and 





 RQ6: Is there an association between community-based naloxone distribution and 
the number of deaths attributed to opioid misuse/overdose per year among adults 25 to 64 
years? 
H06: There is no association between community-based naloxone distribution and 
the number of deaths attributed to opioid misuse/overdose per year among adults 
25 to 64 years. 
H16: There is an association between community-based naloxone distribution and 
the number of deaths attributed to opioid misuse/overdose per year among adults 
25 to 64 years. 
Data Analysis Plan 
Independent Variables 
The independent variables include the number of state-sponsored PDMP trained 
healthcare providers, the number of naloxone community-based distribution center opioid 
prescriptions written and dispensed, the number of naloxone community-based 
distribution center opioid prescriptions with MME above 90, and the number of naloxone 
community-based distribution center opioid naïve patients (patients who have never used 
prescription opioids or have not used prescription opioids in 6 months or more). 
Dependent Variables 
The dependent variables include the number of reported opioid overdoses per year 
among adults 25 to 64 years, the number of opioid addiction treatment admissions per 
year, and the number of opioid-related deaths per year among adults 25 to 64 years.  






Research Questions, Dependent Variables, and Independent Variables and Level of 
Measurement 
Research questions Independent variables Dependent 
variables 
RQ 1: Is there an association between 
the number of state-sponsored PDMPs 
trained healthcare providers per year 
and the number of reported opioid 
overdoses per year among adults 25 to 
64 years? 
 
The number of PDMP 
trained healthcare providers 
per year/ Continuous  






RQ 2: Is there an association between 
the number of state-sponsored PDMPs 
trained healthcare providers and the 
number of opioid addiction treatment 
admissions per year among adults 25 to 
64 years? 
The number of PDMP 
trained healthcare providers 








RQ 3: Is there an association between 
the number of state-sponsored PDMPs 
trained healthcare providers and the 
number of deaths attributed to opioid 
overdose-related deaths per year among 
adults 25 to 64 years? 
The number of state-
sponsored PDMPs trained 
healthcare providers per 
year/ Continuous 






RQ 4: Is there an association between 
community-based naloxone distribution 
and the number of reported opioid 
overdoses per year among adults 25 to 
64 years? 
Community-based naloxone 
distribution (the number of 
opioid prescriptions written 
and dispensed) per year/ 
Continuous 






RQ5: Is there an association between 
community-based naloxone distribution  
and the number of opioid addiction 
treatment admissions per year among 
adults 25 to 64years? 
Community-based naloxone 
distribution (the number of 
opioid prescriptions with 
MME higher than 90mg)/ 
Continuous 
 







RQ 6: Is there an association between 
community-based naloxone distribution 
and the number of deaths attributed to 
Community-based naloxone 
distribution (The number of 
opioid naïve patients)/ 
Continuous 






opioid misuse/overdose per year among 




The manipulation of the data was done using IBM’s Statistical Package for Social 
Sciences. The research adopted descriptive statistics as one of its tools of analysis. 
Descriptive statistics describe the relationship between variables in a sample or population. 
Inferential statistics was also adopted to make inferences about the whole population as 
well as to measure the central tendencies to describe the rate of prevalence. The study also 
used the Analysis of Variance to assess if there is a significant difference between the 
variables. This was to help evaluate whether or not there is a between-group variability or 
within-group variability (error variance). The within-group variability is based on the 
random differences within the population. 
  Multiple regressions were also run with SPSS to find out whether or not there is a 
linear relationship between the dependent and independent variables, the presence of 
homogeneity, absence of outliers, standard distribution errors, as well as single variant and 
multivariate normality. 
 Non-parametric test is used when the assumption of normality is not met, and the sample 
means are not normally distributed. It is sometimes referred to as distribution-free tests.  
Parametric test involves specific probability distributions (e.g., the normal distribution) 
and the tests involve estimation of the key parameters of that distribution (e.g., the mean 
or difference in means) from the sample data.   
However, non-parametric tests may fail to detect a significant difference when 
compared to parametric analysis. The non-parametric test used in this study was the Mann-




or whether observations in one sample tend to be larger than observations in the other. The 
study also used the Kruskal-Wallis test to analyze the variance between the research 
variables. It analyses if there is any difference in the median values of three or more 
independent samples. The data values were ranked in increasing order, and the rank sums 
were calculated. 
Threats to Validity and Reliability 
Validity is the extent to which a concept is accurately measured in a quantitative 
study. There are three major types of validity: Content validity, Construct validity and 
Criterion Validity. Content validity is the extent to which a research instrument accurately 
measures all aspects of a construct. Construct validity is the extent to which a research 
instrument measures the intended construct. Criterion validity is the extent to which a 
research instrument is related to other instruments that measure the same variables (Heale 
& Twyross, 2015). 
Internal validity relates to participants selection, data recording and data analysis 
of the data, while external validity refers to the generalizability of the study and whether it 
can be transferred to other populations (Lakshimi & Mohideen, 2013). 
According to Drost (2011), internal validity refers to the validity of the study, as to 
whether there is a strong or causal relationship between the variables and the effects of any 
confounding factors. There are at least 12 threats to the internal validity of a study. These 
include history, maturation, testing, instrumentation, statistical regression, differential 
selection, experimental mortality, selection-maturation interaction, experimental treatment 




On the other hand, external validity refers to the generalizability of the research 
findings. Some of the threats of external validity include:  
• The extent to which one can generalize from the experimental sample to a 
defined population.  
• The extent to which phonological variables interact with treatment 
variables.  
• Explicit description of the experimental treatment and the Hawthorne effect  
• Multiple-treatment interference 
• Interaction of history and treatment effects.  
• Measurement of the dependent variables and 
•  Interaction of time measurement and treatment effects. 
According to Koziol and Arthur (2011), studies sponsored by the government 
generally involve larger samples that are more representative of the target population due 
to the availability of adequate funds, material, and human resources. State-sponsored 
agencies compiled the PDMP data with all the necessary elements. Due to this, the dataset 
had numerous variables; therefore, there was increased and strong statistical precision. 
Reliability 
The reliability and validity of research depend on the instruments used by the 
researchers to gather data. According to Drost (2011), reliability is the extent to which 
measurements are repeatable when different persons perform the analyses on various 





There are three types of reliability: test-retest reliability, inter-rater reliability and 
internal consistency reliability. Test-retest reliability evaluates the stability of measures 
administered at different times using the same individuals or the same standards. Inter-rater 
reliability establishes the equivalence of ratings obtained with an instrument when used by 
different observers. Reliable measurement will require consistency between different 
raters, and there should be no collaboration between raters. Inter-rater Reliability is 
determined by the coefficient of agreement of the judgment of the raters or Cohen's kappa. 
Internal consistency reliability gives an estimate of the equivalence of sets of items from 
the same test. The Coefficient of internal consistency or Cronbach's alpha is a function of 
the average inters correlations of items and the number of items in the scale. Its value is 
expressed from 0 to 1 (Drost, 2011; Lakshmi & Mohideen, 2013).  
Most government and state-sponsored research have a Cronbach's alpha of at least 
0.9. This study's data is extracted from reliable state data which is used in government 
policymaking. The validity and reliability of the data can be guaranteed since the 
population size is vast, and the data is also used for budgeting purposes. Thus, its accuracy 
can be assured. 
Ethical Procedures 
 All the data collected are readily available to the public on the state's health 
department websites. The IRB requirement was to take the CITI program course for student 
researchers which was completed on Jan 9, 2019, and the NIH web-based training course 





In this section, the study sought to compare the retrospective secondary data using 
observational ecologic study. The ecologic research design considers the rate of exposure 
or exposed person and the rate of disease or the number of cases known.  This study 
involves an assessment of the correlation between exposure rate (the availability of 
prescription opioids through written or dispensed prescriptions) and disease rate (the 
number of cases that use/abuse and/or overdose) by age group and gender. The data was 
taken from both national surveys by the NSDUH from SAMSHA and the websites of the 





Section 3: Presentation of the Results and Findings 
Introduction 
The purpose of this chapter is to present the findings and analyses of the effects of 
state-sponsored PDMPs, trained healthcare providers, and community-based naloxone 
distribution in Florida and Georgia on the prevention and reduction of prescription opioid 
abuse and overdose. Prescription drug abuse and overdose are associated with substantial 
morbidity and mortality rates, as well as social and economic costs.  
In this chapter, the variables explored were: the number of opioid prescriptions 
written in each year, the number of opioid prescriptions with MME above 90 per year, 
the number of opioid-naive patients (i.e. patients who have never used opioid 
prescriptions or have not used in the last 6 calendar months), the number of healthcare 
providers trained to use the PDMP in each year, the number of opioid-related emergency 
room visits and admissions each year, the number of opioid-related admissions into 
treatment centers each year, the number of opioid-related deaths each year, and the age 
and gender of the patients.  
Data Collection and Analyses 
The data for this study were collected from the Department of Public Health 
websites for both the State of Florida and Georgia from the years 2014 to 2018.  
The research questions and hypotheses for the study are as follows:  
RQ1: Is there an association between the number of state-sponsored PDMPs 
trained healthcare providers per year and the number of reported opioid overdoses per 




H01: There is no association between the number of state-sponsored PDMPs 
trained healthcare providers per year and the number of reported opioid overdoses 
per year among adults 25 to 64 years. 
H11: There is an association between the number of state-sponsored PDMPs 
trained healthcare providers per year and the number of reported opioid overdoses 
per year among adults 25 to 64 years. 
RQ2: Is there an association between the number of state-sponsored PDMPs 
trained healthcare providers and the number of opioid addiction treatment admissions per 
year among adults 25 to 64 years? 
H02: There is no association between the number of state-sponsored PDMPs and 
the number of opioid addiction treatment admissions per year among adults 25 to 
64 years. 
H12: There is an association between the number of state-sponsored PDMPs 
trained physicians and the number of opioid addiction treatment admissions per 
year among adults 25 to 64 years. 
RQ3: Is there an association between the number of state-sponsored PDMPs 
trained healthcare providers and the number of deaths attributed to opioid overdose-
related deaths per year among adults 25 to 64 years? 
H03: There is no association between the number of state-sponsored PDMPs 
trained healthcare providers per year and the number of opioid overdose-related 




H13: There is an association between the number of state-sponsored PDMPs 
trained healthcare providers and the number of deaths attributed to opioid 
overdose-related deaths per year among adults 25 to 64 years. 
RQ4: Is there an association between community-based naloxone distribution and 
the number of reported opioid overdoses per year among adults 25 to 64 years? 
H04: There no association between community-based naloxone distribution and 
the number of reported opioid overdoses per year among adults 25 to 64 years. 
H14: There is an association between community-based naloxone distribution and 
the number of reported opioid overdose per year among adults 25 to 64 years. 
RQ 5: Is there an association between community-based naloxone distribution and 
the number of opioid addiction treatment admissions per year among adults 25 to 64 
years? 
H05: There is no association between community-based naloxone distribution and 
the number of opioid addiction treatment admissions per year among adults 25 to 
64 years. 
H15: There is an association between community-based naloxone distribution and 
the number of opioid addiction treatment admissions per year among adults 25 to 
64 years. 
 RQ6: Is there an association between community-based naloxone distribution  and 





H06: There is no association between community-based naloxone distribution and 
the number of deaths attributed to opioid misuse/overdose per year among adults 
25 to 64 years. 
H16: There is an association between community-based naloxone distribution and 
the number of deaths attributed to opioid misuse/overdose per year among adults 
25 to 64 years. 
Descriptive Demographics and Univariate Analysis of the Florida Sample 
 Data were collected from the Florida State Health Department’s PDMP 
(Electronic-Florida Online Reporting of Controlled Substances Evaluation- E-FORSCE) 
website from the years 2014 to 2018. The variables were the total number of prescription 
opioid written per year from 2014 to 2018, the total number of yearly prescriptions with 
MME greater than 90mg (MME>90), the total number of yearly emergency room 
admissions and visits, the total number of healthcare providers trained per year, the total 
number of opioid naïve patients, and the number of prescription opioid written with daily 






Florida PDMP Data 



















































7,520,189 6,917678 6,574,384 6,415,235 6,311,743 
Number of 
RX with daily 
MME>90 
282,980 277,698 206,088 194,561 186,821 
 
Opioid rate per patient’s age range 
25-34 1,200 1,100 1,200 1,250 1,300 
34-44 1,600 1,600 1,500 1,550 1,500 
45-54 2,150 2,200 2,300 2,250 2,050 
55-64 2,600 3,000 2,800 2,750 2,600 
Opioid RX for male & female (ages 25-64) 
Females 4,030,000 4,200,000 4,300,000 4,350,000 4,250,000 





Opioid deaths age range 
25-34 486 733 1031 967 1218 
35-50 959 1486 1831 1733 1651 
Above 50 1583 2140 2426 2463 2394 
 
 
Explanation and Comparison of Variables-Florida 
Total Number of Opioid Prescriptions 
The total number of yearly opioid prescriptions peaked in 2016 and began to 
decline as shown in Figure 2.  
Figure 2 







The Total Number of Morphine Milligram Equivalents (MME) per Opioid 
Prescription 
The total number of MME per opioid prescription has been increasing gradually, 
which in turn increases the addictiveness of the opioid medication, as shown in Figure 3. 
Figure 3 
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The Total Number of Emergency Room (ER) Visits and Admissions 
The number of opioid-related ER visits and admissions increased from 2015 to 
2017; however, the number began to decrease in 2018, as shown in Figure 4. 
Figure 4 
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The Total Number of Opioid-Related Deaths 
The number of opioid-related deaths almost doubled from 2,538 in 2015 to 4,280 
in 2017. This is represented in Figure 5 
Figure 5 
Number of Yearly Opioid-Related Deaths from 2014 to 2018 
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The Number of Healthcare Providers Trained in PDMP 
The year 2015 had the highest number of trained healthcare providers, and there 
was a decrease in the following 2 years. However, the numbers went back up in 2018, as 
shown in Figure 6. 
Figure 6 
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Opioid rate per patient age group 
The opioid rate per 1,000 patient age group remained steady over the years, with 
the 55 64 age groups being the highest consumers as shown in Figure 3.8. 
Figure 9 




Total Number of Opioid prescription for Male and Female 
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Number of yearly opioid prescriptions per gender 
 
Years 
Total Number of Opioid-related deaths by age group 
The total number of opioid-related deaths are highest among people 50 and older over the 
years from 2014 to 2017. 
4,030,000
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Number of yearly opioid-related deaths by age group 
 
Descriptive Demographics and Univariate Analysis of the Georgia Sample 
The Georgia PDMP is also managed by the State’s Department of Health. The 
available data collected were from the year 2014 to 2018. They include the total number of 
prescription opioids written per year; the number of Emergency Room visits & admissions 
from; the number of opioid-related deaths in the state; the number of opioid naïve patients 
(thus patients who have not had any opioid prescriptions in past 6 months or more); and 
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Georgia PDMP Data 
Year 2014 2015 2016 2017 2018 
Number of Opioid 
RX’s                            
8,912,489 8,736,389 8,589,707 8,001,050 7,487,527 
Number of ER 
visits & 
admissions 
9,569 8,484 7,843 8,278 7,359 
 
Number of RX 
with Daily 
MME>90 
249,561 217,821 184,170 172,034 125,140 
Number of Opioid 
Naïve Patients 
320,189 311,743 298,402 224,297 217,359 
Number of Opioid 
Related Deaths 
1,304 1,268 954 1,051 876 
Opioid Rate Per Patient's Age 
Range  
25-34 781,171 681,132 600,542 751,408 651,423 
34-44 1,677,522 1,491,238 899,000 1,110,468 991,575 
45-54 1,740,394 1,639,475 1,225,000 1,568,651 1,409,081 
55-64 1,760,198 1,569,760 1,650,000 1,404,320 1,879,290 
Opioid Per Gender & Age (25-64 years) 




Male 4,352,101 4,211,484 3,705,000 3,304,324 3,094,257 
Opioid Deaths Age Range 
25-34 288 255 231 303 220 
35-44 264 259 279 307 225 
45-54 299 295 298 305 171 
55-64 178 165 189 198 135 
 
Explanation and Comparison of Variables-Georgia 
Total Number of Opioid Prescriptions 
The total number of opioid prescriptions dispensed to patients has been decreasing from 
2014 to 2018 as shown in Figure 3.11. 
Figure 12 
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Total Number of ER Visits and Admissions 
The number of ER visits and admissions peaked in 2017; however, it relatively reduced 
in 2018. 
Figure 13 
The number of Emergency Room visits and admissions, Georgia 
 
Total number of opioid-related deaths 
The number of opioid-related deaths peaked in 2017 just as the number of ER visits 
and admissions and began to decrease. 
Figure 14 
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Total Number of opioid naïve patients 
The total number of opioid naïve patients decreased over the years from 2014 to 2018.  
Figure 15 
Number of opioid naïve patients 
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The total number of prescriptions with daily MME>90 has been decreasing over the years 
from 2014 to 2018. 
Figure 16 
Number of opioid prescriptions with daily MME>90 
 
Opioid rate per Patient Age Group 
The rate of opioid consumption among age groups between 45 to 54 years and 55 
to 64 is among the highest from 2014 to 2018. 
Figure 17 




















Prescription Opioid Consumption between Male and Female Ages 25-64 years 
The data shows that females consume more opioid prescriptions than males in all 
the years compared as presented in Figure 3.17. 
Figure 18 
Opioid RX for male and female 
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The total number of opioid deaths among age groups has been reducing over the 
years from 2014 to 2018. Furthermore, the data also shows that the ages between 35-44 
and 45-54 have the highest mortality rates. 
Figure 19 
Number of opioid-related deaths per age group 
 
 
Descriptive Statistics for Florida Data 
The number of Trained Providers has a mean of 32829.80 (S.D 12783.26). The mean for 
the number of yearly Opioid Prescriptions is 16,162,233.0 (S.D 656227.91). The mean for 
Emergency Room Visits and Admissions per year is 13,058.6 (SD 1,895.13). The mean for 
Opioid-Related Deaths per year is 3,767.2 (SD 734.97). The mean for the MME per year 
is 638.52 (SD 22.82). The mean for Opioid Naïve Patients is 674,784.5 (SD 488,943.13). 
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Descriptive Statistics for Florida                                                                                                                           
 Mean Std Deviation Std Error 
Year Prescriptions 
 
16,162,233 656,227.91 293,474.04 
Trained Providers 
 








3,767.2 734.97 328.69 
MME per Opioid 
RX’s 
 




674,784.8 488,943.14 21,8662.02 
RX Daily MME>90 229,629.6 46,833.28 20,944.48 
 
To test the null hypothesis for the Research Questions 1 to 3 which states that there is no 
association between the number of state-sponsored PDMPs trained healthcare providers 
and the number of opioid overdoses, the number of opioid admissions and the number of 
opioid-related deaths a one-way ANOVA (Analysis of Variance) was conducted using 
SPSS software version 21 and post-hoc test using the Tukey HSD to evaluate pairwise 
differences between means of the variables. The results from the ANOVA analysis 







One-way ANOVA for Florida Data 
Source Sum of Squares Df Mean Square F Sig 
Between 
groups 
1149900086613551.8 6 191650014435591.97 1996.172 .000 
Within 
groups 
2688245461020.12 28 96008766465.01   
Total 1152588332074572.0 34    
In accordance with the post-hoc tests, it is notable that there are significant 
differences within the variables. There is a significant difference between the mean of the 
number of trained providers and the mean of the number of yearly prescriptions (mean 
difference=16,129,403.20) with 95% C.I (15,507,766.81, 16,751,039.59). There is a 
significant difference between the mean of the number of yearly prescriptions and the mean 
of the number of emergency room visits and admissions (mean difference=16,149,174.4) 
with 95% C. I (15,527,538.0, 16,770,810.79). 
 There is a significant difference between the mean of the number of yearly 
prescriptions and the mean of the number of opioid-related deaths (mean 
difference=16,158,465.8) with 95% CI (Confidence Interval) (15,536,829.4, 
16,780,102.19). There is also a significant difference between the mean of the number of 
yearly prescriptions and the mean of the number of prescriptions with MME>90) (mean 
difference= 16,161,594.48) with 95% CI (15.539, 958.09, 16,783,230.87). 
 There is also a significant difference between the number of yearly prescription and 
opioid naïve patients (mean difference=9,414,387.2) with 95% CI (8,792,750.81, 




and the number of prescription with Daily MME>90 (mean difference=15,932,603.4) with 
95% CI (15,310,967.01, 16,554,239.79). There is a significant difference between the mean 
of the number of trained providers and the mean of the number of emergency room visits 
and admission (mean difference=19,771.2) with 955 CI (-601,865.19, 641,407). 
There is a significant difference between the mean of the number of trained 
providers and the mean of the number of opioid-related deaths (mean 
difference=29,062.60) with 95% CI (-592573.79, 650,698.99). There is a significant 
difference between the mean of the number of trained providers and the mean of the 
number of prescriptions with Morphine Milligram Equivalence>90) (mean 
difference=32,191.28 with 95% C I (-589,445.11, 653,827).  
There is a significant difference between the mean of the number of trained 
providers and the mean number of opioid naïve patients (mean difference=6,715,016.00) 
with 95% CI (7,336,652.39, -6,093,379.61). There is a significant difference between the 
mean of the number of trained providers and the mean of the number of prescription with 
Daily MME>90 (mean difference= 196,799.80) with 95% CI (-818,436.19, 424,836.59). 
 There is a significant difference between the mean of the number of emergency 
room visits and admissions and the mean of the number of Opioid-related deaths (mean 
difference=9,291.40) with 95% CI (-641,407.59, 601,865.19). There is a significant 
difference between the mean of the number of emergency room visits and admissions and 
the mean of the number of prescriptions with MME>90 (mean difference=12501.6) with 
95% CI (-786869.6, 811872.9) (mean difference=12,420.08) with 95% CI (-609,216.31, 




emergency room visits and admissions and the mean of the number of opioid naïve patient 
(mean difference= 6,734,787.20) with 95% C.I (-7,356,423.59, -6,122,442.21).  
 There is a significant difference between the mean of the number of emergency 
room visits and admissions and the mean of the number of prescription with Daily MME> 
90 (mean difference= 216571.00) with 95% CI (-838207.39, 405,065.39). There is a 
significant difference between the mean of the number of Opioid-related Deaths and the 
mean of the number of prescriptions with MME>90 (mean difference=3128.68) with 95% 
CI (-618,507.71, 624,765.07). 
There is a significant difference between the mean of the number of Opioid-related Deaths 
and the mean of the number of opioid naïve patients (mean difference= 6,744,078.60 with 
95% CI (-73,65,714.99, -6,122,442.21). 
There is a significant difference between the mean of the number of Opioid-related 
Deaths and the mean of the number of prescriptions with Daily MME > 90 (mean 
difference=225,862.40) with 95% CI (-847,498.79, 395,773.99). There is a significant 
difference between the means of the MME per Prescription and the mean of the number of 
opioid naïve patients (mean difference=6,747,207.28) with 95% CI (-7,368,843.67, -
5656759.7880). There is a significant difference between the means of the MME per 
Prescription and the mean of the number of prescriptions with Daily MME>90 (mean 
difference=22,899.80 with 95% CI (-850,627.47, 39,245.31). There is a significant 
difference between the mean of the number of opioid naïve patients and the mean of the 
number of prescriptions with daily MME >90 (mean difference= 6,518,216.20) with 95% 










































































































      




Descriptive Statistics for Georgia Data 
The yearly prescription opioid has a mean of 8026094.7 (S.D 551516.6). 
emergency room admissions and visits have a mean of 7826.7 (S.D 459.7). The number of 
Opioid-related deaths has a mean of 960.3 (S.D 87.7). The number of Opioid Naïve patients 
has a mean of 246686.0 (S.D 44921.5) and the number of prescriptions with Daily 
MME>90 has a mean of 160448.0 (S.D 31173.9) as shown on Table 3.6 below. 
Table 8 
Descriptive statistics for Georgia-Data 
 Mean Std Deviation Std Error 
 
Number of Opioid 
RX’s 
 
8,345,432.40 589,209.48 263,502.49 
Number of ER 
visits & admissions 
 
8,306.60 827.47 370.06 
RX Daily MME>90 
 
189,745.20 47,129.56 21,076.98 
Number of Opioid 
Naïve Patients 
274,398.00 49,576.24 22,171.17 
Number of Opioid 
Related Deaths 




 To test the null hypothesis for the Research Questions 4 to 6 which states that there 
is no association between community-based naloxone distribution (number of opioid 
prescriptions written and dispensed; the number of opioid prescriptions with MME above 
90; the number of opioid-naïve patients (thus patients who never used prescription opioids 
in six months or more); the number of reported opioid overdoses; the number of addiction 
treatments admissions; and the number of Opioid-related deaths, a one-way ANOVA was 
conducted using SPSS software version 21 and post-hoc test using the Tukey HSD to 
evaluate pairwise differences between means of the variables of the Georgia Data. The 
results from the ANOVA revealed a significant difference in the mean of the variables with 
F (4, 10) = 613.5 p<.001.  See Table 3.7 below for details. 
Table 9 
One-way ANOVA for Georgia Data 
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 Based on the post-hoc tests conducted, there is a significant difference between the 
mean of the number of Prescription opioids per year and the mean of Emergency room 
visits and admissions (mean difference= 8,337,125.80) with 95% C.I (7,835,085.93, 
8,839,165.67). There is a significant difference between the mean of the number of 
prescription Opioids per year and the mean of the number of prescriptions with Daily 
MME>90 (mean difference= 8,155,687.20) with 95% C.I (7,653,647.33, 8,657,727.07). 
There is a significant difference between the mean of the number of prescription opioids 
per year and the mean of the number of Opioid Naïve Patients (mean difference= 
8,071,034.40) with 95% C.I (7,568,994.53, 8,573,074.27). 
 There is a significant difference between the mean of the number of prescription 
opioids per year and the mean of the number of Opioid-related deaths (mean difference= 
8,344,341.80) with 95% C.I (7,842,301.93, 8,846,381.67). There is a significant difference 
between the mean of the number of Emergency room admissions and visits and the mean 
of the number of Prescription Opioid with Daily MME>90 (mean difference= -181438.60) 
with 95% CI (-683,478.47, 320,601.27). There is a significant difference between the mean 
of the number of Emergency room admissions and visits and the mean of the number of 





 There is a significant difference between the mean of the number of emergency 
room admissions and visits and the mean of the number of Opioid-related Deaths (mean 
difference= 7216.00) with 95% CI (-494823.87, 509255.87). There is a significant 
difference between the mean of the number of Prescriptions with Daily MME>90 and the 
mean of Opioid Naïve Patients (mean difference= -84652.80) with 95% C.I (-586692.67 -
417387.07). There is a significant difference between the mean of the number of 
Prescriptions with Daily MME>90 and the mean of the number of Opioid-related deaths 
(mean difference 188654.60) with 95% CI (-313385.27, 690694.47). There is a significant 
difference between the mean on the number of Opioid Naïve patients and the mean of the 
number of Opioid-related deaths (mean difference = 273307.40) with 95% C I (-228732.47, 






Pairwise Differences in Mean and Corresponding 95% Confidence Intervals for Georgia 
Data 



























































    
 
Table 11 
Multiple Linear Regression, Florida Data 
    Model     
Summary 
      
      Change  Statistics    






















Multiple linear regression test was performed to determine the influence of the 
various independent variables on the dependent variable (The number of trained providers 
in the PDMP per year from 2014 to 2018). From the above table, the R square value is 
1.000. This shows the predictor values such as the number of prescriptions with daily 
MME>90 from 2014 to 2018; the number of opioid prescriptions per year from 2014 to 
2018 in Florida; the number of ER visits and admissions per year from 2014 to 2018 in 
Florida; and the number of opioid-related deaths per year from 2014 to 2018 in Florida has 
a significant influence on the number of trained providers in the PDMP. The Durbin-
Watson value of 1.833 is a health assumption that first-order linear auto-correction is 
nonexistent in the multiple linear regression performed. 
Table 12 
Multiple Linear Regression, Georgia Data 
    Model 
Summary 
      
      Change  Statistics    

















1 1.000a 1.000   1.000  4 0  1.703 
 
Multiple linear regression test was also performed to determine the influence of 
the various independent variables on the dependent variable (the number of opioid 
prescriptions per year from 2014 to 2018). From the above table, the R square value is 
1.000. This shows the predictor values such as the number of Opioid prescriptions with 
Daily MME>90 per year from 2014 to 2018; the number of Opioid naive patients (thus 




or more); the total number of Opioid-related deaths from 2014 to 2018 in Georgia; the 
total number of ER visits and admissions per year from 2014 to 2018 in Georgia has a 
significant influence on the number of opioid prescriptions per year from 2014 to 2018 in 
Georgia.  
The Durbin-Watson value at 1.000 means that first-order linear auto-correlation 
are nonexistent in the multiple linear regression performed. 
 
 
Analysis of Research Questions 
Research Question One 
 RQ1: Is there an association between the number of state-sponsored PDMPs trained 
healthcare providers per year and the number of reported opioid overdoses per year among 
adults 25 to 64 years? 
Research Question Two 
        RQ2: Is there an association between the number of state-sponsored PDMPs trained 
healthcare providers and the number of opioid addiction treatment admissions per year 
among adults 25 to 64 years? 
Research Question Three 
RQ3: Is there an association between the number of state-sponsored PDMPs trained 
healthcare providers and the number of deaths attributed to opioid overdose-related deaths 




From the One-way ANOVA and the post-hoc analysis of the Florida data, it can be 
said that the null hypothesis for Research Questions One to Three are false and that there 
are significant differences between the mean of the variables. Research shows that 
prescription opioid optimum therapeutic daily MME range is between 50 and 90 
milligrams. Ranges above 90 milligrams have a high risk of overdose (Chua et al., 2020).  
Research Question Four 
RQ4: Is there an association between community-based naloxone distribution and 
the number of reported opioid overdoses per year among adults 25 to 64 years? 
Research Question Five 
RQ5: Is there an association between community-based naloxone distribution and 
the number of opioid addiction treatment admissions per year among adults 25 to 64 years? 
Research Question Six 
RQ6: Is there an association between community-based naloxone distribution and 
the number of deaths attributed to opioid misuse/overdose per year among adults 25 to 64 
years? 
From the One-way ANOVA and the post-hoc analysis of the Georgia data, it can 
be deduced  that the null hypothesis for Research Questions Four to Six are also false and 
that there are significant differences between the mean of the variables. According to Behar 
et al. (2016) and Coffin et al. (2016), naloxone co-prescribing with prescription opioids is 
associated with a reduction in opioid-related ER visits. Research also shows that the 
implementation of the national opioid overdose and Naloxone Distribution (OEND) has 




(Oliva et al., 2017). Furthermore, the distribution of naloxone kits in pharmacies and 
hospitals per to state’s Public Health directors standing orders and protocols to allow non-
patient specific dispensing of naloxone have reduced opioid-related deaths (Bachyrycz et 
al., 2018). 
Summary 
This research has demonstrated that the introduction of PDMPs and the Surgeon 
Generals standing orders on Naloxone dispensing has had some effects on the considered 
variables over the years compared. The introduction of the standard order prescription by 
the Surgeon General in both states could contribute to the decline in ER visits and 
admissions and the decline in opioid-related deaths in Georgia. However, the rise in opioid-
related deaths in Florida could be due to other confounding factors. The significance of 
these results and how they can be applied towards positive social change would be 





Section 4: Application to Professional Practice and Implications for Social Change  
Introduction 
The misuse of prescription opioids, including abuse, dependence, and overdose, is 
well documented. According to the 2014 National Survey on Drug Use and Health, 15 
million people aged 12 or older used prescription drugs non-medically in the past year. In 
2013, there were 16,235 deaths from prescription opioid overdose. In 2014, the CDC 
declared drug overdose deaths an epidemic (Florence et al., 2016; Kandel et al., 2017). 
The opioid crisis has also resulted in a substantial cost burden to many communities and 
states. The health care costs, criminal justice expenses, and productivity losses 
attributable to opioid misuse were estimated to a total amount of $78.5 billion in 2014 
alone (Chen et al., 2019). 
In this study, I compared the state-sponsored PDMP data for Florida and Georgia. 
The variables were the number of opioid prescriptions written each year, the number of 
opioid prescriptions with MME above 90 each year, the number of opioid naïve patients 
(patients who have never used opioid prescriptions or have not used it in the last 6 
calendar months), the number of healthcare providers trained to use the PDMP, the 
number of opioid-related emergency room visits and admissions each year, the number of 
related opioid admissions into treatment centers each year, the number of opioid-related 
deaths each year, and the gender and age of patients (age range between 25 and 64 years). 




Socio-Ecological Model Theory 
The SEM suggests that an individual’s behavior is integrated into a dynamic 
network of intrapersonal characteristics, interpersonal processes, institutional factors, 
community features, and public policy. The model stipulates that interactions between 
individuals and their environment are reciprocal, implying that the individual is 
influenced by their environment and the environment is influenced by the individual.  
The SEM further assumes that the environment is comprised of different 
overlapping levels. The intrapersonal level encompasses the research participant’s 
knowledge, awareness, attitudes, beliefs, and perceptions. The individual’s family, 
friends, and healthcare providers are important components of the interpersonal level. 
The healthcare institution’s rules, regulations, and general attitude toward research 
comprise the institutional level. 
The community level includes local cultural attitudes, availability of public 
amenities such as transportation, and safety of the neighborhood. The public policy level 
includes local, state, and federal laws regarding socio-behavior. The SEM takes into 
account socio-cultural factors, as well as environmental factors, and their linkages to 
biologic factors. 
Interpretation of the Findings 
From the study on RQ1, I found that almost all the null hypotheses to research 
questions were not valid, while the alternate hypothesis was right. There was however an 
association between the state-sponsored PDMP trained healthcare providers and the 




Florida as well the total number of prescription opioids dispensed decreased over the 
years from 2014 to 2018. Also, in Georgia, the total number of prescription opioids with 
a daily MME>90 decreased over the years.  
On RQ2, the data shows that there is an association between the number of state-
sponsored PDMPs trained healthcare providers per year, the number of opioid addiction 
treatment admissions, and the number of ER visits and admissions among adults 25 to 64 
years (controlled for age group and gender). On RQ2, there was a relationship between 
the PDMPs and the number of opioid addiction treatment admissions. The data showed 
that the total number of ER visits and hospitalizations decreased between 2017 and 2018. 
RQ3 only showed an association between the PDMP and deaths attributed to 
opioid misuse/overdose in Georgia. The total number of opioid-related deaths decreased 
between 2017 and 2018, as did opioid-related deaths by age range. In Florida, however, 
the total number of opioid-related deaths increased between 2017 and 2018. This could 
be due to the high incidence of illicit drugs such as synthetic fentanyl in the state. 
RQ4 to RQ6 showed that the ready availability and accessibility of naloxone 
through state health department standing order, and the ability of non-patients to purchase 
naloxone without a prescription decreased the total number of opioid overdoses, which 
reflects in the reduction of ER visits and admission as well as the number of opioid-
related deaths over the period. 
Limitations of the Study 
Florida started collecting public health data for its PDMP around 2012. However, 




with different duration of implementation made the data analysis difficult. The Florida 
health department has all data available to the general public, while the Georgia health 
department requires Institutional Review Board application, which caused a delay in the 
data gathering process.  
Recommendation 
Future research could include multiple states with varying demographics and 
locations. Standardization of data reporting and regulations to all state-sponsored PDMPs 
could influence any comparison research. From this current study, it was revealed that 
there is a need for states to implement uniform and consistent public health policies and 
guidelines across board to prevent cross-border travel to and from states with relaxed 
policies.The licensure and continuing education requirements for healthcare providers on 
prescribing prescription opioids should be adequate and extensive (Glowacki, 2015; 
Lewis et al., 2015). 
Implications for Professional Practice 
Education and training of healthcare providers on prescription opioid prescribing 
guidelines, proper medication, disposal systems, patient screening, doctor’s office urine 
test, addiction treatment, and proper patient referral processes should be incorporated as 
tools for the control and reduction of prescription opioid abuse/overdose. Furthermore, 
appropriate policies and practices to prevent an increase in illicit opioid drug use such as 
synthetic fentanyl and heroin could reduce opioid-related deaths in general (Hagemeier et 




Research has proven that opioid addiction has heritability rates similar to other 
chronic diseases such as diabetes, asthma, and hypertension (Volkow & Mclellan, 2016). 
Prescription opioid abuse is significantly affected by the lack of structural and social 
determinants of health in the United States public health system. Healthcare providers are 
either undereducated or misinformed about the appropriate use of prescription opioids for 
non-cancer pain management and treatment (Dasgupta et al., 2018; Stratton et al., 2018). 
Therefore, the need for comprehensive education along such lines is paramount.  
Collaboration between healthcare providers to improve trustworthiness as well as 
the use of the lowest effective for the shortest effective duration to achieve the 
appropriate pain management would reduce prescription opioid abuse and reduce 
addiction treatment cases (Volkow & Mclellan, 2016). The influence of the big drug 
manufacturing companies on both state and federal authorities through lobbying and 
funding of advocate group to push false narratives on non-cancer pain management has 
contributed significantly to this prescription opioid epidemic (Stratton et al., 2018). 
Social Change 
Prescription opioid abuse has a disproportionately high prevalence among non-
metropolitan, suburban, and rural area populations due to the increased availability and 
accessibility of prescription opioids by the older population. These medications have 
become easily accessible to young family members who tend to abuse them (Faryar et al., 
2018). PDMPs, education of healthcare providers, and community use of naloxone and 
practice guidelines have reduced misuse, abuse, addiction, diversion, and false 




for effective public health education using social media, print media, and the internet on 
the effects of prescription opioid abuse/overdose on the population. 
Lack of economic opportunities, poor working conditions, depression, 
hopelessness, and lack of social capital are significant contributors to prescription opioid 
abuse in many American communities (Dasgupta et al., 2018). The public health issue of 
opioid abuse should be solved holistically with all social health determinants considered. 
Pharmaceutical companies need to be tightly regulated and focused on their labeling, 
post-marketing surveillance, abuse-deterrent formulations, and use of non-opioid 
alternatives for non-cancer pain management.  
Methods of overdose and addiction treatments as well use of counselors should be 
reviewed continuously by the state PDMPs and public health authorities. Unfortunately, 
recent research shows that the number of opioid prescriptions written in the United States 
is roughly equal to the number of the adult population (Califf et al., 2016). The 
management of non-cancer pain with cognitive behavioral therapy as well as a 
complementary alternate medicine should be considered (Salas et al., 2016).  
Conclusion 
This research has demonstrated that the use of state-sponsored PDMPs, 
availability and accessibility of naloxone, healthcare provider education, patient 
screening, and abuse-deterrent formulations have a significant role in the reduction and 
prevention of prescription opioid overdose among the population, especially those 
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